Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide | Zendy

H Klepzig | Zendy; G. Kober | Zendy; Christian M. Matter | Zendy; H. G. Luus | Zendy; Hanan Schneider | Zendy; Kyle Boedeker | Zendy; W Kiowski | Zendy; Franz W. Amann | Zendy; Doris Gruber | Zendy; Scott Harris | Zendy; Wolfram Burger | Zendy

Open Access

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

Author(s) -

H Klepzig,

G. Kober,

Christian M. Matter,

H. G. Luus,

Hanan Schneider,

Kyle Boedeker,

W Kiowski,

Franz W. Amann,

Doris Gruber,

Scott Harris,

Wolfram Burger

Publication year - 1999

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.1998.1242

Subject(s) - glibenclamide , glimepiride , medicine , sulfonylurea , placebo , diabetes mellitus , sulfonylurea receptor , cardiology , pharmacology , metformin , endocrinology , alternative medicine , pathology

Glimepiride is a new sulfonylurea for diabetes treatment which is supposed to impact less on extra-pancreatic ATP-dependent K+ channels than the conventional drug glibenclamide. This study was performed to evaluate whether this results in a better maintenance of ATP-dependent K+ channel mediated ischaemic myocardial preconditioning.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research